Zynex, Inc. announced that Anthony Scalese, Chief Financial Officer of the company of his intent to resign from such position effective on or about July 6, 2014. Mr. Scalese also agreed to provide transition services to the company on a consulting basis following his departure. Mr. Scalese is resigning to pursue other opportunities and his resignation is not due to a disagreement with the company with respect to any matter relating to the company's operations, policies or practices.
Upon the effectiveness of Mr. Scalese's resignation, Thomas Sandgaard, the company's Chairman and Chief Executive Officer, will assume the role of principal financial and principal accounting officer. The company is actively looking for a replacement Chief Financial Officer.
Zynex, Inc. develops, manufactures, markets and sells medical devices used for pain management and rehabilitation, as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals. The Companyâs devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Companyâs products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave and M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Distributed Complementary, which includes Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces and Bracing, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter and HemeOx tHb Oximeter.
ZYNEX, INC. 
